Bergen Brunswig focusing on supply channel cost-management strategies after calling off Ivax merger.
Executive Summary
BERGEN SUPPLY EFFICIENCIES REMAIN "CENTRAL STRATEGY" AFTER COLLAPSE OF IVAX MERGER agreement, the wholesaler said March 20. "One of Bergen Brunswig's central strategies is to pursue opportunities to manage supply channel costs" through in-house programs, alliances or acquisitions, Bergen said. "Notwithstanding the termination of the Ivax agreement, we will continue to pursue our strategy, recognizing the valuable role that generics play."
You may also be interested in...
Cardinal Plans Generic Cardiolite, Other Moves To Expand Generic Presence
Cardinal Health expects to market its own generic version of Bristol-Myers Squibb's cardiac imaging agent Cardiolite (technetium Tc99m sestamibi) as part of a plan to expand its role in the generic sector
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011